

-continued

```

<220> FEATURE:
<223> OTHER INFORMATION: PPLA-2 forward primer

<400> SEQUENCE: 61

ctactgtggc ctagtgatgag cag                                23

<210> SEQ ID NO 62
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PPLA-2 reverse primer

<400> SEQUENCE: 62

tctctgtagc agttgctgtg tgtct                                25

<210> SEQ ID NO 63
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PPLA-2 probe

<400> SEQUENCE: 63

cgcagcacct gtccagttca tccac                                25

```

What is claimed is:

1. A method for preventing inflammation comprising depleting or sequestering immune lymphocytes.

2. The method of claim 1, further comprising administering to a subject one or more doses of a lymphocyte depletion agent or a lymphocyte sequestering agent or both.

3. The method of claim 1, wherein said immune lymphocytes are group consisting of B lymphocytes, T lymphocytes, NK cells, and platelets.

4. The method of claim 2, wherein said lymphocyte depletion agent is selected from the group consisting of PATG, Thymoglobulin and Alemtuzumab.

5. The method of claim 2, wherein said lymphocyte sequestering agent is FTY720.

6. The method of claim 2, wherein said lymphocyte agent is administered by a route selected from the group consisting of: oral, transdermal, transmucosal, intradermal, subcutaneous, intravenous, and intramuscular.

7. The method of claim 2, wherein said agent is administered with a pharmaceutically acceptable carrier.

8. The method of claim 1, wherein said inflammation is caused by an infection or an injury.

9. The method of claim 8, wherein said injury is ischemic injury.

10. The method of claim 12, wherein said agent is administered to the subject within 7 days before the onset of inflammation.

11. A method for treating inflammation in a subject, comprising depleting or sequestering immune lymphocytes.

12. The method of claim 11, further comprising administering to a subject one or more doses of a lymphocyte depletion agent or a lymphocyte sequestering agent or both.

13. The method of claim 11, wherein said immune lymphocytes are group consisting of B lymphocytes, T lymphocytes, NK cells, and platelets.

14. The method of claim 12, wherein said lymphocyte depletion agent is selected from the group consisting of PATG, Thymoglobulin and Alemtuzumab

15. The method of claim 12, wherein said lymphocyte sequestering agent FTY720.

16. The method of claim 12, wherein said agent is administered by a route selected from the group consisting of: oral, transdermal, transmucosal, intradermal, subcutaneous, intravenous, and intramuscular.

17. The method of claim 12, wherein said agent is administered with a pharmaceutically acceptable carrier.

18. The method of claim 1, wherein said inflammation is caused by an infection or an injury.

19. The method of claim 18, wherein said injury is ischemic injury.

20. The method of claim 12, wherein said agent is administered during or after the infection or injury.

21. The method of 19, wherein said ischemic injury is caused by hemorrhagic shock.

22. The method of 21, wherein said agent is administered before reperfusion.

23. A method for preventing abdominal adhesion, comprising depleting or sequestering immune lymphocytes.

24. The method of claim 23, further comprising administering to a subject one or more doses of a lymphocyte depletion agent or a lymphocyte sequestering agent or both.

25. The method of claim 23, wherein said immune lymphocytes are group consisting of B lymphocytes, T lymphocytes, NK cells, and platelets.

26. The method of claim 24, wherein said lymphocyte depletion agent is selected from the group consisting of PATG, Thymoglobulin and Alemtuzumab.

27. The method of claim 24, wherein said lymphocyte sequestering agent is FTY720.